Δ 9 -THCV behaves as a potent CB 2 receptor partial agonist in vitro. In contrast, it antagonizes cannabinoid receptor agonists in CB 1 -expressing tissues. This it does with relatively high potency and in a manner that is both tissue and ligand dependent.

Delta9-THCV behaves as a potent CB2 receptor partial agonist in vitro. In contrast, it antagonizes cannabinoid receptor agonists in CB1-expressing tissues. This it does with relatively high potency and in a manner that is both tissue and ligand dependent.

Jan 31, 2020 · Δ9-Tetrahydrocannabivarin (THCV) is a cannabis-derived compound with unique properties that set it apart from the more common cannabinoids, such as Δ9-tetrahydrocannabinol (THC). The main advantage of THCV over THC is the lack of psychoactive effects.

THCV was found to suppress inflammatory pathways by down-regulating LPS-induced expression of iNOS, COX-2 and interleukin 1β. THCV mediated suppression of nitrite production (from nitric oxide) was prevented by pretreatment of the macrophages with SR144528.

Compared to THC which demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, THCV acts as a CB1 antagonist and a partial agonist of CB2. Further evidence has also shown that THCV acts as an agonist of GPR55 and l-α-lysophosphatidylinositol (LPI).

Apr 4, 2025 · It acts as a partial agonist at both CB1 and CB2 receptors, binding to them without fully triggering the intense responses THC provokes, no high here. This gentle interaction allows CBG to influence pain, inflammation, and mood subtly yet effectively. ... THCV (tetrahydrocannabivarin) looks like THC’s molecular twin but behaves like its opposite.

Jul 24, 2020 · THCV's activity is complicated: it is implicated as a cannabinoid receptor antagonist by competitively inhibiting THC@CB 1 formation, although other evidence implies that THCV may also be an indirect agonist (Englund et al., 2015).

THCV can activate CB(2) receptors in vitro and decrease signs of inflammation and inflammatory pain in mice partly via CB(1) and/or CB(2) receptor activation.

THCV has also high affinity for CB2 receptors and signals as a partial agonist, differing from both CBD and rimonabant.

Mar 25, 2025 · Its interaction with CB2 receptors suggests neuroprotective potential, particularly in conditions like Parkinson’s and Alzheimer’s disease. THCV also has anti-inflammatory properties, which may benefit those suffering from chronic pain or autoimmune conditions.